Abstract：
Colorectal cancer (CRC) with peritoneal metastases is a complex disease and its management presents significant clinical challenges. In well-selected patients at experienced centers, CRS/hyperthermic intraperitoneal chemotherapy (HIPEC) can be performed with acceptable morbidity and is associated with prolonged survival. Based on the results of recent randomized controlled trials, HIPEC using oxaliplatin after CRS with shortened perfusion periods (30 minutes) is no longer recommended. There is a movement toward utilizing mitomycin C as a first-line intraperitoneal agent with extended perfusion times (90-120 minutes); however, there is currently little prospective evidence to support its widespread use.
摘要：
伴有腹膜转移的结直肠癌（CRC）是一种复杂的疾病，其治疗提出了重大的临床挑战。在经验丰富的中心精心挑选的患者中，CRS/高温腹膜内化疗（HIPEC）可以以可接受的发病率进行，并与延长的生存期相关。根据近期随机对照试验的结果，不再建议在CRS后使用奥沙利铂的HIPEC，灌注期缩短（30分钟）。有一种趋势是利用丝裂霉素C作为延长灌注时间（90-120分钟）的一线腹膜内药物；然而，目前几乎没有潜在证据支持其广泛使用。
